Clinical trials: Neoplasms, Germ Cell and Embryonal
Glioblastoma
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your glioblastoma multiforme.
- Trial name
- NCT01259869
- Testing
- PX-866
- Where
- 7 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Diffuse, Intrinsic Pontine Glioma
A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)
Current therapies for diffuse, intrinsic pontine glioma (DIPG) provide very limited benefit to the patient. The rationale for the use of Antineoplaston therapy in this protocol study derives from experience with subjects from…
- Trial name
- NCT02742883
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Burzynski Research Institute
Testicular Cancer
Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy
Germ cell tumors, a relatively rare disease, but most common malignancy in young males, occur most frequently in testis. The incidence is about 1%, but is increasing in the majority of developed countries.
- Trial name
- GCT (NCT00772694)
- Testing
- sorafenib
- Where
- Poland
- Volunteers
- 20 people
- Sponsor
- Fondation Wygrajmy Zdrowie
Metastatic Melanoma, Skin Cancer
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
Background: Melanoma antigen recognized by T-cells (MART)-1 is a protein present in melanoma cells. An experimental procedure developed for treating patients with melanoma uses the anti-MART-1 F5 gene and a type of virus to make…
- Trial name
- NCT00612222
- Testing
- autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, ALVAC MART-1 Vaccine, aldesleukin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, IDH-wildtype
THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation (THERABIOME-GBM)
This is a pilot or feasibility study to test the study plan and to find out whether enough participants will join a larger study and accept the study procedures.
- Trial name
- THERABIOME-GBM (NCT05326334)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Ottawa Hospital Research Institute
Brain Tumors
Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Bradmer Pharmaceuticals, Inc. (Bradmer) is requesting approval to study the safety of Neuradiab® when combined with Bevacizumab (Avastin) therapy given at a minimum of 30 days after Neuradiab administration in patients with a…
- Trial name
- NCT00906516
- Testing
- Neuradiab in combination with Bevacizumab (Avastin)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Bradmer Pharmaceuticals Inc.
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Germ Cell Tumors, Hepatic Cancer
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
Life-threatening thrombocytopenia (low platelet count) and neutropenia (low white blood count) remain the major dose-limiting toxicities following chemotherapy treatment for cancer.
- Conditions
- Germ Cell Tumors, Hepatic Cancer, Neuroblastoma, Osteosarcoma
- Trial name
- NCT00187109
- Testing
- Recombinant Human Thrombopoietin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Jude Children's Research Hospital
Glioblastoma
TTFields In GErmany in Routine Clinical Care
The purpose of this post-authorisation medical device study is to obtain real life data on the use of tumor-treating fields (TTFields) in patients with newly diagnosed GBM in routine clinical care in Germany.
- Trial name
- TIGER (NCT03258021)
- Testing
- TTFields
- Where
- Germany
- Volunteers
- 710 people
- Sponsor
- NovoCure Ltd.
Metastatic Melanoma
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo.
- Trial name
- NCT00724841
- Testing
- Obatoclax Mesylate, Temozolomide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Gemin X
Malignant Melanoma, Melanoma (Skin)
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
The purpose of this study is to find out if two new treatment cancer vaccines called SCIB1 and iSCIB1+ can be used safely when added to nivolumab (Opdivo) with ipilimumab (Yervoy), or SCIB1 with pembrolizumab (Keytruda).
- Conditions
- Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
- Trial name
- NCT04079166
- Testing
- SCIB1 or iSCIB1+ DNA vaccine
- Where
- 15 sites in United Kingdom
- Volunteers
- 173 people
- Sponsor
- Scancell Ltd
Neuroblastoma
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for…
- Trial name
- NCT04936529
- Testing
- β-glucan, GM-CSF, OPT-821
- Where
- United States
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
Background: Chemotherapy damages cancer cell deoxyribonucleic acid (DNA) so the cells die, and the tumor shrinks. But it may stop working in some people over time.
- Conditions
- Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma, Uterine Cervical Neoplasms
- Trial name
- NCT02487095
- Testing
- Topotecan, VX-970 (M6620)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme
Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)
GERT is a one-armed single-center phase I/II trial. In a first step, dose-escalation of TMZ from 50 mg/m2 to 75mg/m2 together with radiotherapy and cetuximab will be performed.
- Trial name
- NCT00311857
- Testing
- Cetuximab, Temozolomide, Radiation therapy
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Heidelberg University
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Neuroendocrine Tumors, Carcinoid Syndrome
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
The NET-PACS trial is a Prospective Assessment of patients with neuroendocrine tumors and current or prior history of Carcinoid Syndrome or diarrhea undergoing peptide receptor radionuclide therapy with or without telotristat…
- Conditions
- Neuroendocrine Tumors, Carcinoid Syndrome, Diarrhea
- Trial name
- NET-PACS (NCT04713202)
- Testing
- Telotristat ethyl, Peptide Receptor Radionuclide Therapy
- Where
- United States
- Sponsor
- Chandrikha Chandrasekhara
Neuroendocrine Tumors, Prostate Cancer
Dual-Tracer Theranostic PET
This study is designed to obtain positron emission tomography with x-ray computed tomography (PET/CT) imaging data with each tracer pair, providing the imaging data needed to develop new simultaneous dual-tracer imaging…
- Trial name
- NCT05680675
- Testing
- Single-Tracer FDG PET/CT Exam, Single-Tracer Cu64-DOTATATE PET/CT Exam, Single-Tracer Ga68-DOTATATE PET/CT Exam
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Utah
Brain Tumor, Kidney Tumor
Engineering Immune Organoids to Study Pediatric Cancer
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
- Conditions
- Brain Tumor, Kidney Tumor, Neuroblastoma, Sarcoma
- Trial name
- IMMUNEORGANOID (NCT05890781)
- Testing
- Skin biopsy, Fresh tumor sample, Blood sample
- Where
- 2 sites in France
- Volunteers
- 108 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
- Trial name
- NCT02743611
- Testing
- BPX-701, Rimiducid
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Bellicum Pharmaceuticals
Melanoma
Targeted Intervention for Melanoma Prevention
In this study, the researchers will conduct interviews with melanoma patients to describe the sun exposure and sun protection practices of patients and their children.
- Trial name
- NCT00394134
- Testing
- Interview
- Where
- United States
- Volunteers
- 205 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.